title: Living donor pancreas transplantation in Japan.
abstract: OBJECTIVE
  Living-donor pancreas transplants (LDPs) were introduced at Chiba-East National Hospital in 2004, and 12 LDPs have been performed at this institution to date. Based on the outcome of these 12 LDPs, the efficacy and safety of LDPs are herein discussed.
  
  
  METHODS
  Twelve diabetic patients underwent LDPs; ten had simultaneous pancreas and kidney transplants from living donors, one had pancreas transplant after a kidney transplant from a living donor, and one had a pancreas transplant alone from a living donor. The donors were parents or brothers and the ABO blood types were incompatible in three LDPs. The procedures for the donor and recipient operations were performed according to the technique established by the University of Minnesota. Bladder drainage was used in 11 recipients and enteric drainage was used in one patient. Tacrolimus, basiliximab, mycophenolate mofetil, and prednisone were used for induction and immunosuppressive treatment. A splenectomy, double-filtered plasmapheresis, and plasma exchange were added in the ABO-incompatible LDPs.
  
  
  RESULTS
  No complications were observed in the donors during hospitalization. The 1-year survivals of the patients, kidney grafts, and pancreas grafts were 100, 100, and 100%, respectively. The 3-year survivals were 91.7, 90, and 91.7%, respectively. Three patients developed leakage of pancreatic juice and one patient required a surgical procedure. Cytomegalovirus antigenemia was detected in five patients (42%).
  
  
  CONCLUSIONS
  Based on the excellent outcome of the LDPs at this institution, LDPs is therefore expected to become a promising option for the treatment of patients with severe diabetes.
authors.affiliation: Department of Surgery, Chiba-East National Hospital, National Hospital Organization, 673 Nitonacho, Chuo-ku, Chiba 260-8712, Japan. kenmoti@cehprinet.com
authors.forename: Takashi
authors.initials: T
authors.lastname: Kenmochi
authors.forename: Takehide
authors.initials: T
authors.lastname: Asano
authors.forename: Michihiro
authors.initials: M
authors.lastname: Maruyama
authors.forename: Kenichi
authors.initials: K
authors.lastname: Saigo
authors.forename: Naotake
authors.initials: N
authors.lastname: Akutsu
authors.forename: Chikara
authors.initials: C
authors.lastname: Iwashita
authors.forename: Kazunori
authors.initials: K
authors.lastname: Ohtsuki
authors.forename: Akiko
authors.initials: A
authors.lastname: Suzuki
authors.forename: Mariko
authors.initials: M
authors.lastname: Miyazaki
mesh_terms: D000328:Adult; D000368:Aged; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000453:epidemiology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000453:epidemiology / Q000601:surgery; D016030:Kidney Transplantation / Q000379:methods; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents